Axar.az
UP

Axar.Az Logo

Novavax COVID-19 vaccine more than 90% effective in U.S. trial

Home page World
12 Punto 14 Punto 16 Punto 18 Punto

Novavax Inc on Monday said its COVID-19 vaccine was more than 90% effective, including against a variety of concerning variants of the coronavirus in a large, late-stage U.S.-based clinical trial.

Axar.az reports that the study of nearly 30,000 volunteers in the United States and Mexico puts Novavax on track to file for emergency authorization in the United States and elsewhere in the third quarter of 2021, the company said.

The protein-based vaccine was more than 93% effective against the more easily transmissible predominant coronavirus variants that have caused concern among scientists and public health officials, Novavax said.

Protein-based vaccines are a conventional approach that use purified pieces of the virus to spur an immune response, such as those used against whooping cough and shingles.

Date
2021.06.14 / 23:32
Author
Axar.az
Comments
See also

Erdogan spoke about the work of the MES

Forest fires in Turkey: the last 10 fires left...

Taliban militants attack UN Office in Afghanistan

Additional Pfizer jabs to be sent to Georgia

Erdogan in the fire zone: It will not be allowed

The Taliban are attacking major Afghan cities

Sharmazanov: Armenia has lost its sovereignty

The US dismisses 182 Russians from its embassy in Russia

A deadly strain of the coronavirus can appear

Gakharia is funded by Saakashvili - Georgian Dream

Latest
Xocalı soyqırımı — 1992-ci il Bağla
Bize yazin Bağla
ArxivBağla